Baricitinib BARUDX

Baricitinib BARUDX

EUR 65.00

1,100+ vendidos
Preco promocional

Farmacia fisica em Hong Kong, 100% de autenticidade garantida

Destaques do produto

Baricitinib 1 JAK1 JAK2 ， ， RA AS (UC)

Garantias de servico

Envio direto internacionalFarmacia autorizadaRevisado por farmaceuticoGarantia de autenticidade

Especificacoes

Especificacao
2mg*28 comprimidos
SKU: n.d. Categoria: Etiquetas: , , , , , , , Marca:

Informacoes do produto

Nome em ingles
Baricitinib
Nome chines
BARUDX
Nome generico
BARUDX

Especificacoes

Especificacao
2mg*28 comprimidos

Detalhes completos

Indicacoes

BARUDX Janus (JAK) ， • TNF JAK DMARD • (ECMO) COVID-19 • JAK

Mecanismo de acao

Immunosuppressants baricitinib

Farmacologia

Immunosuppressants EMA Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate. Atopic Dermatitis Olumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older

Dosagem

• Detalhes completos ， •

Reacoes adversas

≥1% • (URTI) • (COVID-19) (UTI) •

Package Insert

Indications

BARUDX Janus (JAK) ， • TNF JAK DMARD • (ECMO) COVID-19 • JAK

Dosagem

• Detalhes completos ， •

Reacoes adversas

≥1% • (URTI) • (COVID-19) (UTI) •

Avaliacoes do produto (0)

Filtro: Todas as avaliacoes
5.0★★★★★
0 avaliacoes de clientes0 compras verificadas
Ainda nao ha avaliacoes para este produto.

Descricao

Indicacoes

BARUDX Janus (JAK) ， • TNF JAK DMARD • (ECMO) COVID-19 • JAK

Mecanismo de acao

Immunosuppressants baricitinib

Farmacologia

Immunosuppressants EMA Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate. Atopic Dermatitis Olumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older

Dosagem

• Detalhes completos ， •

Reacoes adversas

≥1% • (URTI) • (COVID-19) (UTI) •

Informacoes adicionais

Especificacao

2mg*28片